Richter Group

Formycon AG is a pharmaceutical company based in Planegg, Germany, specializing in the development and marketing of biosimilar products. Established in 1999, the company has a diverse pipeline that includes FYB201, a biosimilar candidate for Lucentis, which has completed Phase III clinical trials for treating serious eye diseases such as neovascular age-related macular degeneration. Additionally, Formycon is developing FYB202, a biosimilar for Stelara, aimed at treating inflammatory diseases including psoriasis and Crohn's disease, currently in Phase I trials. Another candidate, FYB203, targets Eylea, also used for eye conditions. The company's focus extends to drug delivery systems and it also provides comprehensive analytical and formulation services to the biopharmaceutical industry, including pre-formulation, GMP quality control, and stability testing. Formycon is committed to advancing treatments in ophthalmology, immunology, and other chronic diseases while also offering diagnostic laboratory services.

Quris Technologies is an artificial intelligence innovator focused on transforming the pharmaceutical industry. The company has developed a bio clinical-prediction platform that utilizes AI to enhance the safety and efficacy of new drugs. This fully automated and self-trained platform predicts clinical outcomes more quickly and cost-effectively, while significantly reducing the need for animal testing through the use of patients-on-a-chip technology. By enabling pharmaceutical companies to mitigate the risks and expenses associated with failed clinical trials, Quris aims to improve the drug development process and promote more reliable testing methods.

Finox AG, founded in 2007 and based in Kirchberg, Switzerland, specializes in the development of fertility drugs and innovative delivery devices. The company’s flagship product is BEMFOLA, a recombinant-human follicle-stimulating hormone designed for fertility treatment, accompanied by the BEMFOLA injector pen, a user-friendly, single-use device that enables patients to self-administer their medication. Finox AG aims to provide high-quality and cost-effective fertility solutions and markets its products both in Switzerland and internationally. The company has expanded its presence with locations in several European countries, Australia, and the United States. Finox AG operates as a subsidiary of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

Mediplus is a marketing company based in Curaçao, which covers through its subsidiaries a number of countries in the Latin American region, namely: Ecuador, Peru, Chile and Bolivia.

Next Pharma serves the needs of large private and public hospitals, retail chains as well as government agencies in Brazil and its strength is the detection of cutting edge products for specific niches in the pharmaceutical market place and subsequently their successful registration by the local government authorities.

PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.

Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.